1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Middle East and Africa Metastatic Cancer Drugs Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Middle East and Africa Metastatic Cancer Drugs Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Middle East and Africa Metastatic Cancer Drugs Market Regional Analysis
6.2 Middle East and Africa Metastatic Cancer Drugs Market Revenue 2019-2028 (US$ Million)
6.3 Middle East and Africa Metastatic Cancer Drugs Market Forecast Analysis
7. Middle East and Africa Metastatic Cancer Drugs Market Analysis – by Cancer Type
7.1 Breast Cancer
- 7.1.1 Overview
- 7.1.2 Breast Cancer: Middle East and Africa Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.2 Lung Cancer
- 7.2.1 Overview
- 7.2.2 Lung Cancer: Middle East and Africa Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.3 Liver Cancer
- 7.3.1 Overview
- 7.3.2 Liver Cancer: Middle East and Africa Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.4 Hematological Cancer
- 7.4.1 Overview
- 7.4.2 Hematological Cancer: Middle East and Africa Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.5 Brain Cancer
- 7.5.1 Overview
- 7.5.2 Brain Cancer: Middle East and Africa Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.6 Prostate Cancer
- 7.6.1 Overview
- 7.6.2 Prostate Cancer: Middle East and Africa Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.7 Pancreatic Cancer
- 7.7.1 Overview
- 7.7.2 Pancreatic Cancer: Middle East and Africa Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
8. Middle East and Africa Metastatic Cancer Drugs Market Analysis – by Route of Administration
8.1 Intravenous and Intramuscular
- 8.1.1 Overview
- 8.1.2 Intravenous and Intramuscular: Middle East and Africa Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
9. Middle East and Africa Metastatic Cancer Drugs Market Analysis – by Drug Class
9.1 HER2 Inhibitors
- 9.1.1 Overview
- 9.1.2 HER2 Inhibitors: Middle East and Africa Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.2 Immune Checkpoint Inhibitors
- 9.2.1 Overview
- 9.2.2 Immune Checkpoint Inhibitors: Middle East and Africa Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.3 PARP Inhibitors
- 9.3.1 Overview
- 9.3.2 PARP Inhibitors: Middle East and Africa Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.4 Kinase Inhibitors
- 9.4.1 Overview
- 9.4.2 Kinase Inhibitors: Middle East and Africa Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
10. Middle East and Africa Metastatic Cancer Drugs Market Analysis – by Product
10.1 Branded
- 10.1.1 Overview
- 10.1.2 Branded: Middle East and Africa Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
10.2 Generics
- 10.2.1 Overview
- 10.2.2 Generics: Middle East and Africa Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
10.3 Biosimilars
- 10.3.1 Overview
- 10.3.2 Biosimilars: Middle East and Africa Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
11. Middle East and Africa Metastatic Cancer Drugs Market – Middle East and Africa Analysis
11.1 Overview
11.2 Middle East and Africa
- 11.2.1 Middle East and Africa Metastatic Cancer Drugs Market Breakdown, by Key
Country, 2022 and 2028 (%)
- 11.2.1.1 Middle East and Africa Metastatic Cancer Drugs Market – Revenue and
Forecast Analysis – by Country
- 11.2.1.1 South Africa:
Middle East and Africa Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.1.1 South Africa: Middle East and Africa Metastatic Cancer Drugs Market Breakdown, by Cancer Type
- 11.2.1.1.2 South Africa: Middle East and Africa Metastatic Cancer Drugs Market Breakdown, by Route of Administration
- 11.2.1.1.3 South Africa: Middle East and Africa Metastatic Cancer Drugs Market Breakdown, by Drug Class
- 11.2.1.1.4 South Africa: Middle East and Africa Metastatic Cancer Drugs Market Breakdown, by Product
- 11.2.1.2 Saudi Arabia:
Middle East and Africa Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.2.1 Saudi Arabia: Middle East and Africa Metastatic Cancer Drugs Market Breakdown, by Cancer Type
- 11.2.1.2.2 Saudi Arabia: Middle East and Africa Metastatic Cancer Drugs Market Breakdown, by Route of Administration
- 11.2.1.2.3 Saudi Arabia: Middle East and Africa Metastatic Cancer Drugs Market Breakdown, by Drug Class
- 11.2.1.2.4 Saudi Arabia: Middle East and Africa Metastatic Cancer Drugs Market Breakdown, by Product
- 11.2.1.3 UAE:
Middle East and Africa Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.3.1 UAE: Middle East and Africa Metastatic Cancer Drugs Market Breakdown, by Cancer Type
- 11.2.1.3.2 UAE: Middle East and Africa Metastatic Cancer Drugs Market Breakdown, by Route of Administration
- 11.2.1.3.3 UAE: Middle East and Africa Metastatic Cancer Drugs Market Breakdown, by Drug Class
- 11.2.1.3.4 UAE: Middle East and Africa Metastatic Cancer Drugs Market Breakdown, by Product
- 11.2.1.4 Rest of Middle East and Africa:
Middle East and Africa Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.4.1 Rest of Middle East and Africa: Middle East and Africa Metastatic Cancer Drugs Market Breakdown, by Cancer Type
- 11.2.1.4.2 Rest of Middle East and Africa: Middle East and Africa Metastatic Cancer Drugs Market Breakdown, by Route of Administration
- 11.2.1.4.3 Rest of Middle East and Africa: Middle East and Africa Metastatic Cancer Drugs Market Breakdown, by Drug Class
- 11.2.1.4.4 Rest of Middle East and Africa: Middle East and Africa Metastatic Cancer Drugs Market Breakdown, by Product
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 AbbVie Inc.
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Amgen Inc.
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Bristol-Myers Squibb Company
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 F. HOFFMANN-LA ROCHE LTD.
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Novartis AG
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Astrazeneca
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 MERCK KGaA
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Pfizer Inc. (Arena Pharmaceutical GmbH)
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Johnson and Johnson Services, Inc.
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations